News

Exploring Current Trends in Johnson & Johnson Options Trading

Exploring Current Trends in Johnson & Johnson Options Trading

Examining Options Trading Insights for Johnson & Johnson

Investors are showing a notable bullish interest in Johnson & Johnson. With larger players entering the market, the intricacies of options trading are becoming clearer.

After reviewing the trading history for Johnson & Johnson (JNJ), we discovered 10 specific trades that reveal strong investor sentiments. Around 50% of these trades demonstrate bullish expectations, while about 30% show bearish sentiments.

Out of all the trades analyzed, 5 were puts totaling $552,410, and 5 were calls amounting to $522,817. This balanced activity provides a thorough overview of the market dynamics at play.

Understanding Price Target Predictions

Analyzing both volume and open interest in these trades gives us crucial insights. It seems investors are targeting a price range between $155.00 and $170.00 for Johnson & Johnson in recent months. Pinpointing this price range is vital for grasping market expectations.

Insights on Volume and Open Interest

Looking at volume and open interest gives us important clues for a comprehensive understanding of a stock's performance.

This analytical method sheds light on liquidity and interest levels regarding Johnson & Johnson’s options at various strike prices. We can see a detailed overview of both calls and puts within the $155.00 to $170.00 price range from the last month, assisting traders in formulating their strategies effectively.

Overview of 30-Day Options Activity for Johnson & Johnson

The detailed trading activity uncovers several notable options movements:

Key Options Transactions Highlighted

In the realm of current options trading, here are some significant transactions:

  • Symbol: JNJ — Type: PUT — Sentiment: Bullish — Price: $4.56
  • Symbol: JNJ — Type: CALL — Sentiment: Bullish — Price: $15.59
  • Symbol: JNJ — Type: CALL — Sentiment: Bearish — Price: $13.45
  • Symbol: JNJ — Type: CALL — Sentiment: Bullish — Price: $13.70
  • Symbol: JNJ — Type: CALL — Sentiment: Neutral — Price: $9.60

Snapshot of Johnson & Johnson

Johnson & Johnson is a giant in the healthcare industry, known for its vast size and diversity. Following the divestment of its consumer business, Kenvue, in 2023, the company now primarily operates through its pharmaceutical and medical device divisions, which together account for all sales.

Its pharmaceutical division encompasses various therapeutic areas, including immunology, oncology, and cardiovascular health. At present, more than half of the company’s revenue comes from the United States, highlighting its significant domestic focus.

It's essential to understand the options trading patterns while also evaluating broader market conditions and the company's performance.

Current Market Insights for Johnson & Johnson

  • As for the latest trading volume, it stands at 4,494,400, indicating a slight change with JNJ's price recorded at $164.64, down by 0.11%.
  • New RSI indicators suggest that the stock may be approaching an overbought status.
  • Investors can expect the upcoming earnings report in about a month.

Analyst View on Johnson & Johnson

Recently, 2 market analysts provided their assessments, establishing a consensus target price at $215.00.

  • One analyst from Cantor Fitzgerald downgraded their recommendation to Overweight while maintaining the $215 target.
  • A second analyst reflected similar cautious sentiments, reiterating the $215 target alongside an Overweight rating.

Participating in options trading carries its own risks but also offers the potential for significant rewards. Savvy traders manage these risks through education, flexible strategies, and keeping abreast of market trends. For real-time options trading updates on Johnson & Johnson, utilizing dedicated trading platforms can provide invaluable insights.

Frequently Asked Questions

1. What are the recent trends in Johnson & Johnson's options trading?

Recent trends indicate a mixed sentiment among investors, with about 50% bullish and 30% bearish expectations.

2. What is the target price range for Johnson & Johnson?

Investors have set their sights on a target price range of $155.00 to $170.00 for the stock.

3. How many notable trades were identified?

We found a total of 10 noteworthy trades for Johnson & Johnson in the options market.

4. What is the current market status of Johnson & Johnson?

The current trading volume is 4,494,400, with JNJ priced at $164.64, showing a slight downward movement.

5. What is the consensus among analysts regarding Johnson & Johnson?

The consensus target price among analysts stands at $215.00 following recent evaluations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Virse Revolutionizes Creative Production with AI Canvas

Updated Category News Views 156

A New Era in Creative Workflows These days, the design world is getting a major shake-up thanks to Virse's innovative AI-driven workspace. Based out of Dover, this new system isn't just about boosting tech for the sake of it; it's about making creative production a symphony rather than a cacophony. And, let me tell ya, any time I've loaded up on coffee to prep for a brand...

Continue Reading
MPLX Reports Q3 2026 Results with 12.5% Distribution Hike

Updated Category News Views 34

Another Distribution Hike: 12.5% Bump in Q3 Man, MPLX is at it again, boosting that quarterly distribution by a hefty 12.5%. That's three years running now, marking it up to $4.84 per unit on an annualized basis. In an industry where reliability sometimes feels like a relic, this kind of consistency is a sweet serenade to any income-focused investor's ears. "MPLX is...

Continue Reading
Newcomers, Veterans Elevate NYSE's Tokenization Efforts

Updated Category News Views 100

Breaking New Ground at the NYSE When the bell rings at the NYSE these days, it's not just marking the start of another trading session. It's the sound of change clanging its way onto Wall Street. On November 3, 2026, the NYSE threw its hat deeper into the tokenization ring, a game-changer perhaps. They've roped in some big guns—Securitize, tZERO, Broadridge Financial...

Continue Reading
Lupin Launches HIV Treatment, Secures 180-Day Exclusivity

Updated Category News Views 18

Lupin's Market Move: A Big Step in HIV Treatment There's a fresh gust blowing in the pharmaceutical skies today, as Lupin leaps ahead with the launch of their Raltegravir Tablets in the U.S. The company just bagged FDA approval, putting them on the front lines with a high-stake 180-day exclusivity period for their generic version. For investors keeping tabs on pharma...

Continue Reading
Canton Fair Showcases Cutting-Edge Healthcare Tech 2026

Updated Category News Views 41

Innovation Steals the Show in Guangzhou In a world where tech evolution rarely takes a breather, the 140th Canton Fair's Intelligent Healthcare Zone is like a breath of fresh air. Picture it: a whole arena pulsing with futuristic healthcare gizmos from October 31 to November 4, 2026—it's as if tomorrow swung by for a sneak peek. The event brings together everything from...

Continue Reading
Yunji Rolls Out AI Robots at EquipHotel Paris 2026

Updated Category News Views 90

AI Takes Center Stage in Hospitality When someone mentions a new revolution in hospitality, I usually roll my eyes. But this time, Yunji Technology (HKEX: 02670) is bringing something to the table that's hard to ignore. They’re out in full force at EquipHotel Paris 2026, flaunting their AI-powered collection of service bots with the kind of confidence that says, 'We're...

Continue Reading
Reju Partners with Six Mills to Advance Textile Regeneration

Updated Category News Views 203

Big Moves in Textile Regeneration Now here's a move that's got the fabric world buzzing: Reju, the scrappy textile-to-textile regenerative powerhouse, is teaming up with six mills spread across Europe and the U.S. They’re setting the stage to crank up their polyester recycling game and flood the market with sustainable, eco-friendly fabrics. It's a bold step toward...

Continue Reading
Himel's Latest: Powering Industry and Homes Alike

Updated Category News Views 46

Switching Gears: Himel's New Electrical Frontiers Ah, the humming of motors, the click of switches—it's the backbone of any decent industrial setup or modern home today. Himel isn't messing around when it comes to staying on top of these evolving electrical needs, both in gritty industrial settings and our cozy living rooms. This time, they're taking a serious crack at...

Continue Reading
XPENG Eyes South Korea Entry with Industry Veteran

Updated Category News Views 142

A Veteran's Task in a New Territory Piling onto its international ambitions, XPENG has roped in Lee Man-sik, a seasoned auto industry professional, to break into South Korea. South Korea isn’t just another market—it’s one of the toughest stages for the automotive industry. The customers there are sharp, with a keen eye for tech and quality. So XPENG, trading under...

Continue Reading
Samsung Biologics Hits 'Negligible' ESG Risk Milestone

Updated Category News Views 26

Samsung Biologics Achieves a Low-Risk Triumph You gotta hand it to Samsung Biologics for hitting a 'Negligible Risk' rating. Their latest score? A cool 9.0. That’s like walking into the pharmaceuticals room and getting a standing ovation. It's no small feat—climbing up from a 'Low Risk' rating to the top tier in Morningstar Sustainalytics' playbook. For us spectating...

Continue Reading

Top 5 Most Recently Viewed Articles

EnFin Solar Receivables Trust Receives Ratings from KBRA

Updated Category News Views 525

EnFin Residential Solar Receivables Trust 2024-2 Overview Recently, KBRA has assigned preliminary ratings to three classes of notes that total $324.54 million, issued by EnFin Residential Solar Receivables Trust 2024-2, commonly referred to as EnFin 2024-2. This asset-backed securities (ABS) transaction is secured by residential solar loans, aiming to support solar energy...

Continue Reading
Taxbit's Digital Accord to Shape Future of Compliance

Updated Category News Views 257

Taxbit's Digital Accord: Building a Future in Compliance The third edition of the Digital Accord gathers influential regulators and innovators to strategize the future of digital asset compliance and transparency. Global Leaders Meet in London Gathered in this major global capital, executives from various sectors will dive deep into the essential frameworks that will...

Continue Reading
Centene Corporation Q1 2025 Report Showcases Strong Growth

Updated Category News Views 588

Centene Corporation Reports Strong First Quarter 2025 Results Centene Corporation (NYSE: CNC) has made a notable impact in the healthcare sector, showcasing impressive financial achievements in its first-quarter results. The company reported adjusted diluted EPS of $2.90 for the quarter, reflecting a substantial increase of 28% from $2.26 in the same quarter the previous...

Continue Reading
Theratechnologies Faces Temporary EGRIFTA SV Supply Challenges

Updated Category News Views 111

Theratechnologies Faces Temporary Challenges with EGRIFTA SV Supply MONTREAL - Theratechnologies Inc. (NASDAQ: THTX), a well-known biopharmaceutical company, is currently tackling a potential supply interruption regarding its product EGRIFTA SV. This situation has arisen from an unexpected shutdown at a contract manufacturer’s facility, which followed an FDA inspection....

Continue Reading
Miami International Holdings Achieves Record Trading Figures

Updated Category News Views 281

Overview of Trading Results Miami International Holdings, Inc. (MIH) has recently shared its impressive trading results for December and the entire year of 2024, showcasing strong performance across its U.S. exchange subsidiaries including MIAX, MIAX Pearl, MIAX Emerald, and MIAX Sapphire, as well as MIAX Futures. December 2024 and Full-Year Volume Highlights The overall...

Continue Reading